Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer.
Cell Engineering
Immunotherapy, Adoptive
Lymphocytes, Tumor-Infiltrating
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
12
12
2022
entrez:
10
1
2023
pubmed:
11
1
2023
medline:
13
1
2023
Statut:
ppublish
Résumé
Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient's case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) in conjunction with IL-2 and immune-checkpoint blockade. Complete and durable tumor remission was observed after three TIL infusions consisting of 1.4×10
Identifiants
pubmed: 36627144
pii: jitc-2022-005847
doi: 10.1136/jitc-2022-005847
pmc: PMC9835940
pii:
doi:
Substances chimiques
Antibodies
0
TRPS1 protein, human
0
Repressor Proteins
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Immunol. 2020 Aug;217:108456
pubmed: 32376504
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
Int J Mol Sci. 2022 Feb 25;23(5):
pubmed: 35269712
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8
pubmed: 21933959
Int J Cancer. 1999 Oct 22;84(5):506-10
pubmed: 10502728
Adv Cancer Res. 2006;95:1-30
pubmed: 16860654
Nat Med. 2022 Apr;28(4):635-636
pubmed: 35314844
Front Bioeng Biotechnol. 2019 Aug 13;7:194
pubmed: 31457007
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374